GSK Delivers EPS of 104.7p Before Major Restructuring PharmaLive.com (press release), PA - Our MAGE-3 vaccine, is making good progress and last year we signed an exclusive licensing deal with AFFiRiS to develop two Alzheimera s disease vaccines, ... |
StandoutStocks.com: "Stocks that Standout" picks for today are ... Trading Markets (press release), CA - The human trial was conducted by the HIV Vaccine Trials Network (HVTN), and funded by the National Institute of Allergy and Infectious Disease (NIAID), ... |
Raptor Pharmaceuticals Announces Completion of Patient Enrollment ... FOXBusiness - ... human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases. ... |
Why GM crops are dangerous People & the Planet, UK - If GM foods on the market are causing common diseases or if their effects appear only after long-term exposure, we may not be able to identify the source of ... |
Goodness found in real food Georgia Straight, Canada - Proponents of rooibos claim the tea soothes digestive problems and anxiety too. Red Espresso drinks are served at Delaneya s, Beans on Lonsdale, Wicks Cafe, ... |
Cytori Patent Allowance Expands Celution System Protection for ... Centre Daily Times, PA - The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, ... |
Ivivi Technologies and Grupo Venta Internacional, SA de CV Sign an ... GlobeNewsWire (press release), CA - ... strategic partners to pursue the cardiac market and others, such as osteoarthritis, neurology and other inflammatory-related conditions if FDA marketing ... |
Extavia's Launch Foreshadows Novartis' Future Intentions in the ... Market Wire (press release) - "Pharmaceutical Business Review" reported recently that Novartis is likely using Extavia's launch to train and strengthen its neurology sales force in ... |
Get a Deep Insight into the US Flavors & Fragrances Market Earthtimes (press release), UK - ... and aroma of vitamins, minerals, bleaches, antioxidants and other added active ingredients. Through 2012, the cosmetic and toiletry market is expected ... |
Raptor Pharmaceuticals Announces Completion of Patient Enrollment ... FOXBusiness - In the six-month, open-label clinical trial, UC San Diego enrolled a total of 12 adolescent NASH patients receiving a twice daily oral dose of cysteamine ... |
